Budde, E., Sehn, L., Matasar, M., Schuster, S., Assouline, S., Kuruvilla, J., Kim, W., Cheah, C., Shadman, M., Dietrich, S., Ku, M., El-Sharkawi, D., Gutierrez, N., Wei, M. C., Yin, S., Sit, J., Tracy, S., Sabalvaro, F., Peneul, E., Bartlett, N. (2025). Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study. Blood. https://doi.org/10.1182/blood-2025-5352